Shaji Kumar, MD, a hematologist at the Mayo Clinic and chair of the Plasma Cell Disorders Scientific Committee at the American Society of Hematology, discuses the standard of care in newly diagnosed myeloma.
Shaji Kumar, MD, a hematologist at the Mayo Clinic and chair of the Plasma Cell Disorders Scientific Committee at the American Society of Hematology, discuses the standard of care in newly diagnosed myeloma.
According to Kumar, the standard of care is currently a proteasome inhibitor in combination with immunomodulatory drugs or monoclonal antibodies. For patients who are transplant-eligible, induction therapy with dexamethasone is used prior to a single transplant. After the transplant, patients received lenalidomide maintenance (Revlimid). If that patient is high-risk, daratumumab (Darzalex) plus bortezomib, lenalidomide, dexamethasone (VRd) is used.
If the patient is ineligible for transplant, daratumumab is used until disease progression. For high-risk disease, VRd light is used with an effort to also use a proteasome inhibitor or other immunomodulatory drug.
0:08 | The current treatments that we use for newly diagnosed myeloma, are essentially combinations of proteasome inhibitors, immunomodulatory drugs or monoclonal antibodies. Patients who are eligible for a stem cell transplant often get induction therapy with dexamethasone, has a single transplant and goes on lenalidomide maintenance. If they are high risk, we try to use 4 drug combinations, including daratumumab plus VRd, then onto single or 2 transplants and then to drug maintenance therapy. Non transplant eligible patients get started with daratumumab and often continue on therapy until progression. In people with high risk disease, we tend to use VRd light, but typically try to get a proteasome inhibitor and immunomodulatory drug in there.
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
February 22nd 2025In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.
Read More
Key Trials From ASH 2024 Impact Treatment for Plasma Cell Disorders Going Forward
February 20th 2025Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.
Read More